Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.

Bortezomib chemotherapy can cause temporary skin rashes.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.

Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.

Tislelizumab can cause cutaneous lupus erythematosus.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Dutasteride may help shrink prostate cancer tumors.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Dupilumab for eczema may cause hair loss.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Dutasteride is approved to help manage prostate enlargement.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

The cancer drugs bortezomib and lenalidomide cause skin side effects in many patients.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.

Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.